The highly effective anticancer agent doxorubicin (Dox), is a frontline drug used to treat a number of cancers including leukemias, ovarian, prostate, breast, and lung cancer. While Dox has a high level of activity against cancer cells, treatment is often complicated by doselimiting cardiotoxicity. For many years, this debilitating side effect is thought to originate from the drug's direct activity in the mitochondria of cardiac cells, while recent studies have shown that these are primarily downstream effect from nuclear damage. Our lab has developed a mitochondrially-targeted derivative of Dox that enables the selective study of toxicity generated by the presence of Dox in the mitochondria of H9c2 rat cardiomyocytes. We demonstrate that mitochondria-targeted doxorubicin (mtDox) lacks any direct nuclear effects, which allows the cardiomyocytes to undergo mitochondrial biogenesis. This recovery response compensates for the mitotoxic effects of Dox and prevents cell death in cardiomyocytes. In accordance with these findings, cardiac toxicity was only observed in Dox but not mtDox treated mice. This study provides valuable insight into the development of methods to effectively limit the debilitating cardiotoxic effects of Dox, and potentially of other chemotherapeutics that exert effects on multiple subcellular organelles..
Introduction
Anthracyclines such as doxorubicin (Dox) are highly effective chemotherapeutic agents in widespread use for treatment of a variety of cancers including leukemias, ovarian, breast and lung cancer. (1) Since the initial discovery and development of Dox as an antitumor agent in the 1960s, a variety of cellular mechanisms of its potent cytotoxic activity have been identified. (2) The primary mode of action is thought to be through binding at the topoisomerase II (TopoII)-DNA interface to form covalent TopoII-DNA cleavage complexes, ultimately disrupting DNA replication and transcription. (3, 4) Through this process, the formation of TopoII cleavage complexes result in the generation of nuclear DNA (nDNA) double stranded breaks (DSBs) leading to the induction of apoptosis. In addition, Dox is a redox active compound that can cause cell death by generating reactive oxygen species (ROS), which can lead to lipid peroxidation and oxidative DNA lesions.
While Dox is an extremely potent anticancer agent, its clinical use is often complicated by dose-limiting cardiotoxicity, causing congestive heart failures in 20% of patients.(5) At the cellular level, anthracycline-induced cardiomyopathy has long been associated with mitochondrial dysfunction -in particular the generation of high levels of ROS due to redox cycling of Dox at complex I of the electron transport chain (ETC). (6, 7) Alterations in iron and calcium homeostasis have also been identified as contributing factors. Furthermore, TopoII has also been observed in mitochondria (8) , although the contributions of mitochondrial topoisomerase inhibition to cardiotoxicity have only just begun to be explored. (9) Recently, nDNA damage induced by interaction of TopoII was shown to be responsible for the cardiotoxic effects of Dox in mouse models. (10, 11) Dox-induced mitochondrial dysfunction may be primarily dependent upon changes in the mitochondrial transcriptome resulting from nDNA damage rather than the direct mitotoxic effects (10) , consistent with previous findings linking Dox-induced cardiotoxicity to a suppression of mitochondrial biogenesis response resulting from a decrease in nuclear-encoded members of the mitochondrial transcriptome. (12) Under many environmental stresses such as exercise or oxidative damage, cardiac cells are able to adjust to these circumstances by simply generating new, functional mitochondria through the process of mitochondrial biogenesis. (13) However, in the presence of nDNA damage upon Dox treatment, mitochondrial biogenesis is impaired resulting in the death of cardiomyocytes. (12) Organellespecific contributions of Dox toxicity have yet to be fully dissected, largely due to the lack of available tools for selectively targeting drugs to a single subcellular compartment until recent years.
Aside from anthracyclines, mitochondrial dysfunction has also been associated with the mechanism of action for other chemotherapeutic agents such as cisplatin (14) , which have been exploited in the development of new cancer therapeutics. (15) (16) (17) The susceptibility of cancer cells to mitochondrial disruption is due to metabolic changes in cancer cells associated with high rates of glycolysis, which does not occur in cells belonging to other tissues such as the heart. {Fulda, 2010 #29}(ref) While the therapeutic potential of harnessing the mitochondrial disruptive effects of Dox has been contemplated for over a decade (18) , only recently have specific molecular targeting strategies been employed to deliver Dox to mitochondria. Such strategies include liposome encapsulation (19) , chemical conjugation of mitochondrial targeting moieties (20, 21) chemical modification (22) , and nanoparticle encapsulation (23) , all of which have demonstrated the capacity to induce cell death in cancer cells, validating this therapeutic strategy. Particularly promising is the ability of these targeted compounds to overcome clinically relevant resistance mechanisms that exist outside of mitochondria. (20) (21) (22) Previous work has demonstrated that mitochondria-targeted Dox (mtDox, see Figure 1A for structure) is able to inhibit TopoII activity in vitro, leading to the induction of apoptotic cell death in cancer cells, while evading resistance mechanisms such as the upregulation of Pgp efflux pumps in the cellular membrane. (20) This phenomenon has been observed for a number of targeted anticancer agents and is likely the result of direct mitochondrial sequestration. (24) We propose that by leveraging this targeting approach, we can probe and eliminate the aforementioned nuclear effects associated with Dox-induced cardiotoxicity. These findings demonstrate that mitochondrial targeting is a promising way to reduce the cardiotoxic nuclear effects in Dox-treated cardiomyocytes. This study also highlights the potential use of subcellular targeting to probe the organelle-specific contributions of secondary toxicity associated with drug treatment.
Methods and Materials
Cell Culture. A2780 and H9c2 (2-1) rat cardiomyocytes were obtained from ATCC. Peptide and drug conjugate synthesis and characterization. Solid-phase synthesis, doxorubicin-peptide conjugation and purification were performed as briefly described.(ref)
Briefly, peptides were synthesized using standard FMOC chemistry, succinic anhydride was then conjugated to the N-terminus of the peptide while on resin. The peptides were cleaved from resin, precipitated in ether, and lyophilized. Doxorubicin was then conjugated to the peptide in a 2:1 molar ratio, using HBTU (3 equiv) and DIPEA (6 equiv.) in DMF overnight. The doxorubicinpeptide conjugate was then purified using RP-HPLC on a preparative C18 column. The identity of the final conjugate was confirmed using electrospray ionization mass spectrometry, and purity was determined to be > 95% using analytical RP-HPLC on a C18 column with a H2O-acetonitlre (0.1% TFA) gradient. Dox and mtDox concentrations were determined by absorbance in ddH2O
at 488 nm using a molecular extinction coefficient of 11 500 M -1 cm -1 . 
Results and Discussion
mtDox uptake, localization and lack of nuclear damage in H9c2 cells.
Our lab has previously demonstrated that mtDox ( Figure 1A ) localizes to mitochondria of both HeLa and A2780 human cancer cell lines (20) . In this study, the uptake and localization of PicoGreen staining of mitochondria ( Figure S2 ). These observations serve to confirm that mtDox is localized in matrix of H9c2 mitochondria where it is able to interact directly with mtDNA.
The lack of any direct nuclear effect of mtDox was also confirmed by testing for the presence or absence of nDNA DSBs. The generation of DSBs resulting from TopoII poisoning in the nucleus has previously linked to be the major source of cardiotoxic effects of Dox. In H9c2
cells, the presence of DSBs induced by Dox was confirmed by immunoblotting for γ-H2AX
histone in the nucleus, a commonly used marker specific for nDNA lesions ( Figure 1D ). In contrast, no nDNA DSBs were observed for mtDox treated cells, despite its previously confirmed capacity to act as a TopoII poison. Likewise in A2780 cells, Dox, but not mtDox generated an increase of γ-H2AX above the baseline level. Overall, in H9c2 cells mtDox has equivalent mitochondrial uptake as Dox but lacks any nuclear localization and thus direct nDNA damage. This selective activity makes mtDox an excellent tool to probe the cardiotoxic effects resulting from mitochondrial dysfunction induced by Dox in the absence of any direct nuclear damage.
Comparison of mitochondrial dysfunction and time course of damage
To detect the presence of any direct induction of mitochondrial dysfunction, the ATP levels as well as the rate of tricarboxylic acid (TCA) activity of H9c2 cells was assessed upon treatment with Dox or mtDox ( Figure 2A ). Both compounds resulted in similar decreases in total ATP levels. A decrease in TCA cycle activity was also observed upon exposure to Dox, and to a higher degree with mtDox. The mitochondrial metabolic consequences of Dox and mtDox treatment were further analyzed by probing the flux of electrons through various complexes of the ETC ( Figure 2B ). For Dox, the overall reduction of ETC activity is solely attributed to a decrease of complex I activity, owing to its ability to redox cycle specifically with this
In contrast, mtDox is more promiscuous in its reduction of ETC flux and affects complex I and complex II+III. Surprisingly, there was an increase in activity at complex IV compared to baseline level.
In order to efficiently generate ATP, ETC flux maintains a highly negative inward mitochondrial membrane potential. Upon treatment with mtDox, there is a drop in the mitochondrial potential that is evident after just 30 min of treatment ( Figure S3 ). This explains the decrease in overall ATP levels despite the increased proton flux generated at Complex IV.
Despite the comparable mitochondrial uptake, Dox does not induce a similar potential decrease;
likely due to it only has a single positive net charge.
Next, the ability of these compounds to induce mitochondria-specific damage over time was assessed. After six hours of exposure, both mtDox and Dox generated high levels of ROS in H9c2 cells ( Figure 3A ). While ROS levels increased over 24 hours for Dox, ROS levels of While an increase in number of mitochondria may compensate for the mitochondrial dysfunction, damaged mitochondria may also be removed through mitophagy. Indeed by inhibiting this pathway using 3-methyladanine, further increases in mitochondrial volume were observed ( Figure S4 ). This indicates that there is some fraction of damaged mitochondria that are cleared by mitophagy concurrently with the increase in this organelle through mitochondrial biogenesis.
In order to further validate these changes in mitochondrial number, levels of mitochondrial proteins were evaluated. Using an ELISA based assay, the relative levels of While only NRF1 levels increased significantly compared to untreated with mtDox treated cells, both NRF1 and TFAM levels were 5-fold higher in mtDox treated cells compared to Dox. Taken
together, these findings demonstrate the ability of mtDox to induce mitochondrial biogenesis in cardiomyocytes to ensure their survival while Dox, in the presence of nDNA damage, are unable to recover from mitochondrial dysfunction due to impaired mitochondrial biogenesis.
Systemic and cardiac-specific toxicity in vivo is not observed with mtDox administration Finally, the overall in vivo toxicity in mice treated with Dox or mtDox was evaluated by determining MTD (maximum tolerated dose). At the dosing regimen of 3mg/kg/day for 5 days, Dox and mtDox treated mice maintained less than 10% weight loss ( Figure 6A ). Next, CK (creatine kinase) levels were measured in serum samples from treated mice as a marker for cardiac toxicity. Interestingly, only Dox treated mice had significant increase in CK levels compared to untreated mice ( Figure 6B ). In addition, Dox treated mice had CK levels ~8 fold higher than that of untreated and ~4 fold higher than that of mtDox treated mice. These findings demonstrate that mtDox does not induce systemic or cardiac-specific toxicity in mice in accordance with the in cellulo data.
Conclusions
Given the off-target toxicity of Dox, it is an attractive proposition to produce derivatives of this drug with specific subcellular activity in an effort to maintain toxicity against cancer cells but reduce unwanted secondary toxicity in normal cells. The nuclear effects of Dox were eliminated through mitochondrial sequestration, allowing us to selectively study the importance of nDNA damage in cardiomyocyte toxicity upon drug treatment. In this study, we demonstrated that mitochondria-targeting significantly reduced toxicity of Dox toward cardiomyocytes, in accordance with recent reports in animal models that show nDNA damage plays a major role in anthracycline-induced cardiotoxicity. Although short-term mitochondrial dysfunction was observed in cardiomyocytes upon treatment with mtDOX, these effects were compensated for by mitochondrial biogenesis and do not persist at treatment concentrations where this compound exhibits anticancer activity. As demonstrated previously by the ability of mtDox to evade resistance mechanisms, combined with its reduced toxicity in cardiomyocytes and mice, mitochondria-targeting presents a promising strategy for the development of novel chemotherapeutics. Thus, subcellular targeting of Dox enables us to simultaneously study and eliminate the key cellular mechanism of cardiotoxicity. Furthermore, targeted compounds are powerful tools that can be used to deconvolute the organelle-specific effects for drugs that possess a wide range of cellular activity. A greater understanding of these cellular mechanisms will allow for the development of new pharmaceutical intervention strategies that have the ability to eliminate highly undesirable off-target effects while maintaining potent anticancer activity. 
